Sarah E. Pinder
Nature · 2004–2018
A researcher in the Science corpus: 4 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Papers from Sarah E. Pinder's perspective
Ordered by how strongly the researchers Sarah E. Pinder trusts endorse each paper. Same corpus, a different order for every researcher.
- Tissue microarrays for rapid linking of molecular changes to clinical endpoints. (American Journal of Pathology)
- Expert Commentary. (Histopathology)
- Validation of Tissue Microarray Technology in Breast Carcinoma (Laboratory Investigation)
- Molecular portraits of human breast tumours (Nature)
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications (Proceedings of the National Academy of Sciences of the United States of America)
- ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
- Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma (Nature)
- Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition (Nature)
- The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. (Genome Research)
- The Nottingham prognostic index in primary breast cancer (Breast Cancer Research and Treatment)
Their papers
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups (2012) — 5,719 citations
- A randomised phase III trial of carboplatin compared with docetaxel in BRCA1/2 mutated and pre-specified triple negative breast cancer “BRCAness” subgroups: the TNT Trial (2018) — 811 citations
- The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes (2016) — 1,612 citations
- Expression of luminal and basal cytokeratins in human breast carcinoma (2004) — 615 citations